Wednesday October 18, 2017 0 comments
ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced its shares of common stock were approved for listing on The NASDAQ Capital Market.
Trading on The NASDAQ Capital Market will commence on Oct. 20. The Company's trading symbol will continue to be "AYTU."
"The company's listing on The NASDAQ Capital Market is a major milestone for Aytu, and I'm pleased with the progress we have made in the two years since our formation,” said Josh Disbrow, Aytu’s CEO.
“In a short period of time we've successfully built a portfolio of novel, urology-centric products and have scaled a fully-integrated specialty commercial organization.
“To augment our operational progress, we believe that listing on NASDAQ will help the company further diversify our shareholder base and provide better liquidity and exposure for the company as we continue on our growth trajectory."
Aytu currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging.
Aytu is also developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress.